Article
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Urologic oncology - 1 Jan 2022
Nientiedt Cathleen, Budczies Jan, Endris Volker, Kirchner Martina, Schwab Constantin, Jurcic Christina, Behnisch Rouven, Hoveida Shirin, Lantwin Philippa, Kaczorowski Adam, Geisler Christine, Dieffenbacher Svenja, Falkenbach Fabian, Franke Desiree, Görtz Magdalena, Heller Martina, Himmelsbach Ruth, Pecqueux Carine, Rath Mathias, Reimold Philipp, Schütz Viktoria, Simunovic Iva, Walter Elena, Hofer Luisa, Gasch Claudia, Schönberg Gita, Pursche Lars, Hatiboglu Gencay, Nyarangi-Dix Joanne, Sültmann Holger, Zschäbitz Stefanie, Koerber Stefan A, Jäger Dirk, Debus Jürgen, Duensing Anette, Schirmacher Peter, Hohenfellner Markus, Stenzinger Albrecht, Duensing Stefan
Abstract excerpt
BACKGROUND: Mutations in DNA damage repair genes, in particular genes involved in homology-directed repair, define a subgroup of men with prostate cancer with a more unfavorable prognosis but a therapeutic vulnerability to PARP inhibition. In current practice, mutational testing of prostate cancer patients is commonly done late i.e., when the tumor is castration resistant. In addition, most sequencing panels do...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.